La cadena de opciones muestra datos clave de las opciones de acciones de ABVC BioPharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para ABVC BioPharma..

ABVC BioPharma (NASDAQ:ABVC) Bolsa, Cadena de Opciones

ABVC BioPharma

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

ABVC BioPharma Inc

The dust is beginning to settle from the 2024 election, and companies are starting to digest what a second Trump term means for business. On the campaign trail, Candidate Trump promised another round of tariffs on foreign goods, but it remains to be seen what promises actually translate into law once the administration comes to power.&nbsp;
Some companies like Steve Madden are attempting to get ahead of the curve by <a href="https://www.benzinga.com/24/11/41862692/steve-madden-announces-plans-to-move-production-to-avoid-trump-tariffs-but-theres-a-catch">moving production out of China now</a>, but others aren't as nimble and will likely bear the brunt of higher costs. Which public companies are likely to be hit hardest by tariff expansion? Here&#8217;s a list of 4 stocks you might want to consider selling before the next trade war salvo.
<h2 class="wp-block-heading">Methodology</h2>
Each company chosen for this list faces at least one of the following issues:
<ul>
<li>Reliance on imports, especially goods from China </li>
<li>Limited ability to pass higher costs onto customers </li>
<li>Lack of negotiating power with suppliers&nbsp;</li>
<li>Thin margins that could make it challenging to absorb costs </li>
</ul>
The retail industry is already bracing for higher costs. According to the National Retail Foundation, companies are preparing for these additional costs by raising prices on a variety of goods that could cost consumers between $46 billion and $76 billion in purchasing power. Retail will be a major theme amongst these stock picks, especially in areas where customers expect low prices and have substantial alternatives.
<h3 class="wp-block-heading">Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</h3>
Dell has been one of the market's biggest winners since the start of 2023. The company has re-entered the S&amp;P 500 and its stock price has soared from under $40 in March 2023 to over $130 as of this writing. The stock has pulled back a bit since hitting an all-time high of $179 in May, and more pain could be on the way if the proposed tariffs come to be.
Dell sells a variety of electronics, from computers and laptops to cloud and networking solutions. This line of electronics depends on affordable printed circuit boards (PCBs), capacitors, resistors, casings, and assembly operations, and much of this company infrastructure is located in China. Additional tariffs on these components could force Dell to either raise prices faster than customers see reasonable or relocate some of their production outside of China. Either solution could hamper future stock growth. Dell is currently rated a Buy, but the <a href="https://www.benzinga.com/quote/DELL/analyst-ratings">most recent analyst reports</a> put the consensus price target at $117, which is below the current market price.
<h3 class="wp-block-heading">Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>)</h3>
If you or your spouse are primary education teachers, you likely have spent a lot of time in Five Below looking for school supplies, affordable electronics, student rewards, and perhaps some candy for the lounge. The company sells a variety of merchandise at highly discounted prices, and many of its electronic products are imported from China.
Five Below gets hit from both sides in a potential tariff war. Not only is the company heavily reliant on Chinese imports, but its business model leaves very little room to raise prices. Customers who see higher prices at specialty retailers like Five Below may just take their business to higher-end competitors like Target Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>). Analysts currently rate FIVE stock as a Hold with an average price target of $129. However, the three most recent analyst reports (Truist, BofA Securities, and Evercore ISI) only had an average price target of $89, which is about where shares are currently trading. BofA analyst Lorraine Hutchinson <a href="https://www.cnbc.com/2024/11/06/trump-proposed-tariffs-consumer-prices.html">noted in her downgrade</a> that Five Below sources more than 20% of its products from China and lacks the pricing power to pass those costs onto consumers.
<h3 class="wp-block-heading">Lowe's Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>)</h3>
Another big winner from the past two years could be facing more headwinds if tariffs come to fruition. Lowe's has benefited from the home price boom as millions of Americans tapped their expanding home equity for upgrades and renovations following COVID. LOW shares shot from a pandemic low of $86 to $258 by December 2021 and recently made a new all-time high at $270 a few weeks ago. However, if we use history as a guide, Lowe's stock had a choppy ride during the first round of tariffs in 2017.
Lowe's sells high-end appliances like washing machines, dryers, refrigerators, water heaters, and other important (and imported) home goods. Not only will the company face higher costs on these expensive goods, but consumers who have already tapped chunks of home equity may put off new projects or rush to buy before the tariffs kick in. From 2017 to 2020, LOW shares exhibited high volatility with four different 15% corrections. With more tariffs on tap and consumers stretched thin, Lowe's profits could take a hit in the coming months. The company reports earnings on November 19 and investors will be looking for clues on how tariffs could affect its bottom line.
<h3 class="wp-block-heading">Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)</h3>
Another stock up big this year, and another company under pressure from the incoming administration. Walmart didn't suffer as much as the broader indices during the 2022 bear market, but the stock has roared to life in 2024. WMT shares are up over 60% year-to-date, including an eye-popping 41% in the last six months. The company has beaten analyst earnings expectations in each of the previous eight quarters as well.
In recent years, Walmart has sought to divest itself from China by moving some production to India, but Chinese imports still make up <a href="https://www.reuters.com/business/retail-consumer/walmart-shifts-india-china-cheaper-imports-2023-11-29/">about 60%</a> of the company's products. It's unlikely that much more production will be moved out of China by the time tariffs take effect, and Walmart doesn't have the supplier negotiating power that a company like Costco Wholesale Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) does. Additionally, Walmart's Every Day Low Price model runs on razor-thin margins. In July, Walmart reported a <a href="https://www.macrotrends.net/stocks/charts/WMT/walmart/net-profit-margin">net profit margin of 2.34%</a>. While not as low as some previous reports, Walmart has consistently seen its net margin drop below 3% since the first Trump administration, and the company may not have the pricing power to pass additional tariff costs onto its customers.
Take the guesswork out of investing with a handpicked portfolio of value stocks that consistently outperforms the S&amp;P 500. Invest in a proven, time-tested selection designed for long-term growth. <a href="https://www.benzinga.com/premium/ideas/perfect-portfolio/?utm_source=RD-1115">Click to get access now.</a>
Image via Shutterstock

Opinion

Trading Ideas

COST

DELL

FIVE

4 Stocks to Sell Before Trump's Tariffs Take Effect

Needham analyst Laura Martin maintains Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) with a Buy and raises the price target from $8.5 to $9.5.

News

Price Target

Analyst Ratings

NEXN

Needham Maintains Buy on Nexxen International, Raises Price Target to $9.5

In the current session, Aptiv Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) is trading at $53.09, after a 1.73% decrease. Over the past month, the stock decreased by 25.95%, and in the past year, by 34.77%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1731699923_0.png" alt="Past Year Chart" />

<h3>Comparing Aptiv P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Aptiv has a lower P/E than the aggregate P/E of 28.77 of the Automobile Components industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1731699923_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

APTV

Price Over Earnings Overview: Aptiv

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) with a Buy and maintains $33 price target.

Reiteration

PPBT

HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $33 Price Target

Rumors

Legal

JNPR

Watching Juniper Networks; Shares Move Lower As Traders Circulate Research Report Suggesting DOJ Examining Depositions Of Hewlett Packard Enterprise And Juniper Networks' Executives And Third-Party CID Responses, Preparing To Decide Case As Early As Next Week

<h3 class="wp-block-heading">Weed Is Not Legal In Florida But Medical Cannabis Retail Footprint Grows Nonetheless</h3>
RISE Dispensaries, a cannabis retail chain owned by Green Thumb Industries Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GTII#CSE">GTII</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTCQX">GTBIF</a>), opened RISE Dispensary Orlando on Good Homes Road on Friday, Nov. 8. Located at 725 Good Homes Road, the new West Orlando location expanded RISE Dispensaries' retail footprint in Florida to 21 locations and 99 nationwide.
Cannabis giant Curaleaf Holdings, Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CURA#TSX">CURA</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTCQX">CURLF</a>) opened a new medical dispensary in Miami in October. Curaleaf Miami Bird Road, located at 8868 SW Bird Rd. in Miami, brought the company's Florida store count to 66 locations, with 151 dispensaries total nationwide.
Trulieve Cannabis Corp. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/TRUL#CSE">TRUL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>), one of the biggest supporters of Amendment 3 which was rejected by Florida voters earlier this month and would have legalized recreational cannabis in the Sunshine State, additionally expanded its already substantial retail footprint statewide.
October store opening celebrations were held at:
<ul>
<li>Trulieve Bonita Springs South Tamiami, located at 28811 South Tamiami Trail, Unit 12, and Trulieve St. Augustine A1A, located at 3945 A1A South on Oct. 18;</li>
<li>Trulieve Orlando West Colonial, located at 7225 West Colonial Drive, Unit 100 on Oct. 25; and</li>
<li>Trulieve Lake Placid, located at 413 U.S. Highway 27, on Nov. 1.</li>
</ul>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">New Cannabis Stores In Six States And Canada</h3>
Illinois cannabis sales reached a major milestone in July, with sales surpassing $1 billion, as announced by Governor JB Pritzker‘s office. The burgeoning industry continues to grow by the day with new stores launching cannabis sales and events celebrating the plant. Stash Dispensaries recently announced the return of&nbsp;Sesh Haunted City, a special haunted house event to commemorate Sesh&#8217;s third anniversary.
C3 Industries, a multi-state cannabis company dedicated to crafting premium consumer experiences, recently opened High Profile Cannabis Shop Pineville at 35 Macadoodle Lane, its 9th retail location in Missouri and 29th nationwide.
Cannabis concept store Gotham held a grand opening event in October for its new Brooklyn, New York City location. The expansive 4,000-square-foot storefront is located in the heart of Williamsburg on Kent Avenue and South 2nd Street in The Refinery at Domino.
Sweetspot Farms, a new premium cannabis dispensary, is officially open at 111 High Ridge Rd. in Stamford, Connecticut, offering medical and recreational customers a modern and welcoming retail experience. Founded by two Stamford natives, Sweetspot aims to improve access to legal and regulated cannabis for qualified locals who depend on plant-based products for an improved quality of life.
SLO CAL Roots celebrated the grand opening of its third dispensary, Root One, in Guadalupe, California in October. Root One is the latest location from SLO CAL Roots, a Central Coast cannabis company founded in 2003 by local growers Austen Connella and Kristin Kordich.
Hashstoria, a cannabis dispensary co-founded by hip-hop icon Raekwon the Chef of Wu-Tang Clan fame, media personality Charlamagne Tha God, civil rights attorney Bakari Sellers and entrepreneur Jedd Canty hosted the official grand opening celebration in downtown Newark, New Jersey on Wednesday, Nov. 13. It's located at 799-805 Broad Street in the historic Four Corners district.
High Tide Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/HITI#TSXV">HITI</a>) (FSE: 2LYA) Canna Cabana retail cannabis store, located at 97 Bath Road, Kingston, Ontario, began selling recreational cannabis products and consumption accessories for adult use on Oct. 31. This opening marked the 186th Canna Cabana branded retail cannabis location in Canada, the 72nd in the province of Ontario, and the first in Kingston for the Canadian retail cannabis giant.

Cannabis

Entrepreneurship

Retail Sales

CSE:GTII

CSE:TRUL

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

GTII

HITI

TCNNF

TRUL

TSX:CURA

TSXV:HITI

Medical Marijuana Footprint Grows In Florida As Legalization Push Fizzles, And Other New Cannabis Stores

Needham analyst Laura Martin maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Buy and raises the price target from $110 to $130.

Needham Maintains Buy on Walt Disney, Raises Price Target to $130

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) with a Buy and maintains $10 price target.

CMPX

HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target

HC Wainwright &amp; Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) with a Buy and maintains $32 price target.

SGMT

HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target

HC Wainwright &amp; Co. analyst Yi Chen reiterates Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) with a Buy and maintains $15 price target.

KALA

HC Wainwright & Co. Reiterates Buy on Kala Bio, Maintains $15 Price Target

Keurig Dr Pepper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) has outperformed the market over the past 15 years by 2.32% on an annualized basis producing an average annual return of 14.04%. Currently, Keurig Dr Pepper has a market capitalization of $45.06 billion. 
Buying $1000 In KDP: If an investor had bought $1000 of KDP stock 15 years ago, it would be worth $7,196.06 today based on a price of $33.22 for KDP at the time of writing.
<h3>Keurig Dr Pepper's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699205_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Keurig Dr Pepper 15 Years Ago Would Be Worth This Much Today

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) has outperformed the market over the past 10 years by 6.46% on an annualized basis producing an average annual return of 17.48%. Currently, HCA Healthcare has a market capitalization of $87.70 billion. 
Buying $100 In HCA: If an investor had bought $100 of HCA stock 10 years ago, it would be worth $506.91 today based on a price of $339.83 for HCA at the time of writing.
<h3>HCA Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699201_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today

Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) has outperformed the market over the past 10 years by 18.87% on an annualized basis producing an average annual return of 29.89%. Currently, Fabrinet has a market capitalization of $9.04 billion. 
Buying $1000 In FN: If an investor had bought $1000 of FN stock 10 years ago, it would be worth $13,993.98 today based on a price of $249.31 for FN at the time of writing.
<h3>Fabrinet's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699196_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Fabrinet Stock In The Last 10 Years

First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) has outperformed the market over the past 20 years by 6.83% on an annualized basis producing an average annual return of 15.15%. Currently, First Citizens BancShares has a market capitalization of $30.11 billion. 
Buying $100 In FCNCA: If an investor had bought $100 of FCNCA stock 20 years ago, it would be worth $1,728.18 today based on a price of $2152.02 for FCNCA at the time of writing.
<h3>First Citizens BancShares's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699191_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FCNCA

If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,700 Today

HC Wainwright &amp; Co. analyst Edward White reiterates 60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) with a Neutral.

SXTP

HC Wainwright & Co. Reiterates Neutral on 60 Degrees

Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) has outperformed the market over the past 15 years by 1.85% on an annualized basis producing an average annual return of 13.57%. Currently, Johnson Controls Intl has a market capitalization of $56.41 billion. 
Buying $100 In JCI: If an investor had bought $100 of JCI stock 15 years ago, it would be worth $684.45 today based on a price of $84.45 for JCI at the time of writing.
<h3>Johnson Controls Intl's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699187_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Johnson Controls Intl 15 Years Ago Would Be Worth This Much Today

Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) has outperformed the market over the past 20 years by 1.26% on an annualized basis producing an average annual return of 9.59%. Currently, Crown Castle has a market capitalization of $44.95 billion. 
Buying $1000 In CCI: If an investor had bought $1000 of CCI stock 20 years ago, it would be worth $6,268.48 today based on a price of $103.43 for CCI at the time of writing.
<h3>Crown Castle's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699182_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Crown Castle Stock In The Last 20 Years

Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) has outperformed the market over the past 20 years by 2.84% on an annualized basis producing an average annual return of 11.16%. Currently, Texas Instruments has a market capitalization of $184.14 billion. 
Buying $100 In TXN: If an investor had bought $100 of TXN stock 20 years ago, it would be worth $822.22 today based on a price of $201.85 for TXN at the time of writing.
<h3>Texas Instruments's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699176_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Texas Instruments 20 Years Ago Would Be Worth This Much Today

Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) has outperformed the market over the past 15 years by 15.86% on an annualized basis producing an average annual return of 27.59%. Currently, Comfort Systems USA has a market capitalization of $15.82 billion. 
Buying $1000 In FIX: If an investor had bought $1000 of FIX stock 15 years ago, it would be worth $40,251.81 today based on a price of $444.38 for FIX at the time of writing.
<h3>Comfort Systems USA's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699171_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Comfort Systems USA 15 Years Ago Would Be Worth Today

CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) has outperformed the market over the past 5 years by 8.02% on an annualized basis producing an average annual return of 21.4%. Currently, CRH has a market capitalization of $66.88 billion. 
Buying $1000 In CRH: If an investor had bought $1000 of CRH stock 5 years ago, it would be worth $2,673.92 today based on a price of $98.52 for CRH at the time of writing.
<h3>CRH's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699167_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,700 Today

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ABVC BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/abvc-stock-quote/">ABVC</a>) just reported results for the first quarter of 2024.<ul><li>ABVC BioPharma reported earnings per share of -40 cents.</li><li>The company reported revenue of $1,205.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/abvc-stock-earnings-abvc-biopharma-for-q1-of-2024/">ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024

ABVC Biopharma files to sell 1M shares of common stock for holders

ABVC BioPharma, Inc. (ABVC) has issued an update. ABVC BioPharma has announced corrections to a previous press release concerning their licensing d...

ABVC BioPharma Corrects Licensing Deal Financials

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ABVC BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/abvc-stock-quote/">ABVC</a>) just reported results for the second quarter of 2024.<ul><li>ABVC BioPharma reported earnings per share of -9 cents.</li><li>The company reported revenue of $117,142.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/abvc-stock-earnings-abvc-biopharma-for-q2-of-2024/">ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024

ABVC BioPharma GAAP EPS of -$0.09

An announcement from ABVC BioPharma, Inc. (ABVC) is now available. ABVC BioPharma, Inc. has recently updated its corporate presentation, details of...

ABVC BioPharma Releases Corporate Presentation Update

ABVC BioPharma (ABVC) announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has receiv...

ABVC BioPharma receives $50,000 in incremental licensing fees

ABVC BioPharma receives $50,000 in incremental licensing fees, shares climb

Reports Q3 revenue $389,276 vs $15,884 last year. Improved Cash Position: The Company's cash and cash equivalents reached $137,344 as of September ...

ABVC BioPharma reports Q3 EPS (2c) vs (82c) last year

ABVC BioPharma GAAP EPS of -$0.02, revenue of $0.38M

ABVC

Press Releases

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Health Care

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

Comments

ABVC BioPharma

ABVC BioPharma (ABVC) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL